Claim Your Author Page
OBJECTIVES To compare 2005 and 1995 ethics guidelines from journal editors to authors regarding requirements for institutional review board (IRB) approval and conflict-of-interest (COI) disclosure.… (More)
Background: The Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been evaluated for patients with MF in the phase 3 COMFORT studies. In both trials, ruxolitinib prolonged OS, reduced splenomegaly,… (More)
Background: MF is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, cytopenias, debilitating symptoms, and progressive BM… (More)
Background: The phase 3 COMFORT trials demonstrated that the Janus kinase (JAK)1/JAK2 inhibitor RUX reduces spleen volume, prolongs overall survival (OS), and improves MF−related symptoms and… (More)
We have adopted a different approach in pairs trading with NASDAQ 100 Index future (NQ) and Dow Jones Industry Average Index future (YM). Generally speaking, stocks in NASDAQ 100 Index tend to be… (More)
e22132Background: Advances in cancer immunotherapy and targeted therapy have improved clinical outcomes for patients with advanced melanoma. However, there is a lack of understanding of patients’ e...
The strong government intervention and irrational investment behavior from large group of individual investors have posted challenge to quantitative investors. Many have given up their research… (More)